Recursion reports FY2022 net loss $239.5M; cash $549.9M; pipeline advances

RECURSION PHARMACEUTICALS, INC.

2022-FY EPS reported -$1.36 revenue$39,843,000

Net loss of $239.5M for FY2022, up from $186.5M in FY2021; Q4 net loss $57.5M.
Revenue of $39.8M (FY2022) vs $10.2M prior year, driven by Roche-Genentech collaboration.
Cash, cash equivalents and investments $549.9M as of Dec 31, 2022, up from $516.6M.
Initiated five clinical trials in 2022; expects top-line data for REC-994 (CCM) in 2H 2024 and REC-3964 (C. diff) safety/PK data in 2H 2023.
Released RxRx3 open-source cellular imaging dataset and MolRec application in January 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-23-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.